


## Reply to the Letter to the Editor from Egorin

**In Response:** Shortly after publication of our article in the November 1, 2007, issue of *Clinical Cancer Research*, we became aware that a conversion error led to incorrectly low carboplatin plasma ultrafiltrate AUC, impacting the scaling of the  $x$  axis in Fig. 2B and the carboplatin plasma ultrafiltrate results in Table 4. This results in median carboplatin plasma ultrafiltrate AUC of 4.77 mg/mL-min (and not as suggested 1.33 mg/mL-min). The conversion error, however, did not impact the correlation between carboplatin exposure and drug toxicity or clinical outcome. The corrected Fig. 2B is presented here.



**Fig. 2.** B, relative thrombocytopenia as a function of carboplatin plasma ultrafiltrate AUC (mg-min/mL;  $R^2 = 0.26$ , Pearson correlation coefficient 0.51,  $P < 10^{-3}$ ).

Markus Joerger  
Department of Oncology and Hematology,  
Cantonal Hospital,  
St. Gallen, Switzerland

Jan H.N. Schellens  
Department of Medical Oncology,  
The Netherlands Cancer Institute,  
Amsterdam, the Netherlands

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

# Clinical Cancer Research

## Reply to the Letter to the Editor from Egorin

Markus Joerger and Jan H.N. Schelleus

*Clin Cancer Res* 2008;14:2517.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/14/8/2517.2>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/14/8/2517.2>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.